What is HC Wainwright’s Forecast for AQST FY2026 Earnings?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for Aquestive Therapeutics in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.56) for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million.

Several other research analysts have also commented on the company. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a report on Friday. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research note on Friday. Finally, Lake Street Capital dropped their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $2.64 on Tuesday. The company has a market capitalization of $261.02 million, a P/E ratio of -5.87 and a beta of 2.76. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $6.23. The stock has a 50-day simple moving average of $3.05 and a 200-day simple moving average of $4.07.

Institutional Trading of Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AQST. Vanguard Group Inc. lifted its holdings in shares of Aquestive Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after buying an additional 82,958 shares during the period. Geode Capital Management LLC raised its position in Aquestive Therapeutics by 5.7% in the third quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after acquiring an additional 90,543 shares in the last quarter. State Street Corp lifted its holdings in Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after acquiring an additional 512,682 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Aquestive Therapeutics by 6.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock worth $3,505,000 after purchasing an additional 61,200 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after purchasing an additional 621,614 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.